The TREatment of severe Atopic eczema Trial (TREAT)
Research type
Research Study
Full title
A Randomised Controlled Trial Assessing the Effectiveness, Safety and Cost-effectiveness of Methotrexate versus Ciclosporin in the Treatment of Severe Atopic Eczema in Children: The TREatment of Severe Atopic Eczema Trial (TREAT)
IRAS ID
182752
Contact name
Carsten Flohr
Contact email
Sponsor organisation
Kings College London University
Eudract number
2015-002013-29
ISRCTN Number
ISRCTN15837754
Duration of Study in the UK
2 years, 7 months, 30 days
Research summary
TREAT is a study for children and young people with severe, difficult to manage eczema. Eczema treatment aims to reduce skin inflammation, relieve itching and prevent flare-ups. Usually, this can be achieved by regularly applying moisturisers and steroid creams. Although most children grow out of their eczema over time, in a small group of patients the disease is so severe that specialist medicines are needed.
One way of treating severe eczema is to use medicines that help to dampen down the body’s immune system. Two medicines that are used in this way are methotrexate and ciclosporin. This study aims to find out which of these two medicines is the best to use in treating severe eczema in children and young people. We want to compare the two treatments in terms of:
- how well they work
- how they affect flare ups
- the impact of the treatment on the patient’s quality of life
- side effects or other problems that patients might experience when taking these medicines.We will recruit patients aged 2 to16 years with severe, difficult to manage eczema, attending one of the hospitals that are taking part in the study.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
15/EE/0328
Date of REC Opinion
16 Jan 2016
REC opinion
Further Information Favourable Opinion